 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| MK-8507 / Merck (MSD), MK-8591B / Merck (MSD), islatravir (MK-8591) / Merck (MSD)
Clinical: Merck press release on a safety issue in their clinical trial of investigational once-weekly islatravir + MK-8507 (a non-nucleoside reverse transcriptase inhibitor). https://t.co/om5hirwhY4 (Twitter) - Nov 19, 2021